Meier F, Niederländer C, Djanatliev A, Gantner-Bär M, Höllthaler J, Voigt W, Schöffski O, Kolominsky-Rabas P, Emmert M (2013)
Publication Language: English
Publication Type: Journal article, Original article
Publication year: 2013
Publisher: Wiley-Blackwell: No OnlineOpen / Elsevier
Book Volume: 16
Pages Range: A406
Journal Issue: 7
DOI: 10.1016/j.jval.2013.08.480
Prostate cancer (PCA) is the most common cancer in men worldwide. However, there is disagreement about the benefits of existing screening programs. This is mainly due to low specificity of currently utilized biomarkers. This can lead to both inappropriate medical treatment and increasing costs of care. For the future, many biotechnological developments are promising, but not all will be affordable for routine screening. The question is how much a complementary biomarker to prostate-specific antigen (PSA)-test may cost which would be applied to avoid false-positive results.
APA:
Meier, F., Niederländer, C., Djanatliev, A., Gantner-Bär, M., Höllthaler, J., Voigt, W.,... Emmert, M. (2013). Health Economic Evaluation of a Contemplementary Biomarker for Hypothetical Prostate Cancer Screening in Germany. Value in Health, 16(7), A406. https://doi.org/10.1016/j.jval.2013.08.480
MLA:
Meier, Florian, et al. "Health Economic Evaluation of a Contemplementary Biomarker for Hypothetical Prostate Cancer Screening in Germany." Value in Health 16.7 (2013): A406.
BibTeX: Download